Biohit Oyj Full Year 2023 Earnings: Beats Expectations

Biohit Oyj (HEL:BIOBV) Full Year 2023 Results

Key Financial Results

• Revenue: €13.1m (up 19% from FY 2022).
• Net income: €1.85m (up 208% from FY 2022).
• Profit margin: 14% (up from 5.5% in FY 2022). The increase in margin was driven by higher revenue.
• EPS: €0.12 (up from €0.04 in FY 2022).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Biohit Oyj Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 5.6%. Earnings per share (EPS) also surpassed analyst estimates by 9.1%.

The primary driver behind last 12 months revenue was the Europe, Other segment contributing a total revenue of €5.70m (44% of total revenue). The largest operating expense was General & Administrative costs, amounting to €4.09m (62% of total expenses). Over the last 12 months, the company's earnings were enhanced by non-operating gains of €26.0k. Explore how BIOBV's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Medical Equipment industry in Finland.

Performance of the Finnish Medical Equipment industry.

The company's shares are down 1.8% from a week ago.

Risk Analysis

You still need to take note of risks, for example - Biohit Oyj has 2 warning signs (and 1 which is a bit concerning) we think you should know about.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.